Non-Muscle Invasive Urothelial Carcinoma

Cretostimogene Grenadenorepvec Boosts Complete Response Rates, Lessens Progression of NMIBC
The oncolytic immunotherapy drug cretostimogene grenadenorepvec has demonstrated groundbreaking results for the treatment of high-risk (HR) Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) based on new topline data from the phase III BOND-003 trial. CG Oncology has reported that 82 of 110 patients (74.5%) involved in the trial met the primary endpoint of complete response at any time after receiving single agent cretostimogene. At 12 months, 97.3% of patients were free from progression to MIBC. At 12 and 24 months or greater, a total of 63.5% and 56.6% of patients remained in response, ...
Advertisement

Latest News

Advertisement

Urothelial Carcinoma Knowledge Hubs

Curated clinical content based on urothelial cancer types, therapies, and technologies

Urothelial Carcinoma
Urothelial Carcinoma

Conference Coverage

Advertisement
Section Editor

Advertisement
Latest News